BioSpace News Archive

StageZero Life Sciences announced that it will release its fourth quarter and year end 2021 operational results before the market open on Friday April 1, 2022.

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate -linker technology, announced that Philipp Probst, Ph.D., Associate Director of ADC Research at Araris, will present data on the company’s linker technology at the 12th Annual World ADC London Conference.

MediWound Ltd. announced a poster and oral presentation of its EscharEx® clinical data at the 35th Symposium on Advanced Wound Care Spring Conference taking place in Phoenix, Arizona on April 6-10, 2022.

CLS Americas, a subsidiary of Clinical Laserthermia Systems AB, today announced the company’s TRANBERG® Thermal Therapy System will be used by Focalyx Technologies, developer of image-guided fusion target devices, to conduct a 20-patient, Phase I clinical study titled, “Targeted MRI/US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”

Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the appointment of Angela M. Thedinga, MBA, MPH, to its Board of Directors.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the year ended December 31, 2021.

Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the fourth quarter and full year ended December 31, 2021 and provides business highlights.

Laekna Therapeutics, a clinical-stage global biotechnology company，announced the appointment of Jeff Porter, Ph.D. as the Chairman of its Scientific Advisory Board.

AbbVie (NYSE: ABBV) today announced that data from its neuroscience portfolio will be presented at the 2022 American Academy of Neurology (AAN) Annual Meeting.

Sumitomo Dainippon Pharma Oncology, Inc., today announced that the first patient has been dosed in the Phase 1/2 study of DSP-5336, an inhibitor of menin binding to mixed-lineage leukemia (MLL) protein, in patients with relapsed or refractory acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL).